Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Declines By 13.8%

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 879,600 shares, a decrease of 13.8% from the October 31st total of 1,020,000 shares. Currently, 1.5% of the company's shares are short sold. Based on an average trading volume of 278,800 shares, the days-to-cover ratio is currently 3.2 days.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of CNTX. State Street Corp boosted its holdings in shares of Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after buying an additional 25,300 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics in the 3rd quarter valued at approximately $89,000. Ally Bridge Group NY LLC boosted its holdings in shares of Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company's stock valued at $3,782,000 after buying an additional 1,160,281 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock valued at $3,246,000 after buying an additional 1,290,323 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Stock Up 1.3 %

Shares of CNTX traded up $0.02 on Friday, hitting $1.52. The company's stock had a trading volume of 45,803 shares, compared to its average volume of 205,331. Context Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $2.75. The firm's fifty day moving average price is $1.93 and its 200-day moving average price is $2.07. The firm has a market capitalization of $114 million, a price-to-earnings ratio of -1.67 and a beta of 2.25.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). As a group, equities analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CNTX shares. D. Boral Capital started coverage on Context Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $9.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $6.80.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.